Fig. 2

JAK2i-mediated PDGFRβ accumulation in TNBC cells. a IC50 scatter plot of a large panel of cancer cell lines (n = 982) for Ruxolitinib derived from genomics of drug sensitivity in cancer database (http://www.cancerrxgene.org). Table shows detailed analysis of geometric mean wherein the number of breast cancer cell lines is shown in red dots. b Prediction of Kaplan-Meier survival analysis in TCGA patients using data derived from cell line treated with Ruxolitinib and computed based on machine-learning (ML) model. See methodology for details of the analysis. c SUM159PT cells were continuously treated with 5 μM AZD1480 for 6 days and analyzed using receptor tyrosine kinase array. d Dose-dependent PDGFRβ accumulation in response to AZD1480. SUM159PT and MDA-MB-231 cells were treated with different concentrations of AZD1480 for 24 h and indicated proteins were determined by western blot. e SUM159PT cells were treated with different concentrations of two JAK2-specific inhibitors and PDGFRβ levels were determined by western blot. f SUM159PT cell were reversed transfected with 10 nM of JAK1 and JAK2 pool siRNAs for 48 h and PDGFRβ levels were determined by western blot. g Western blot analysis of PDGFRβ protein levels in a panel of human breast cancer lines (n = 22). Cell lines were divided based on their respective subtypes.h A panel of selected breast cancer and near-normal cell lines were reverse-transfected with 10 nM PDGFRβ siRNA and cell viability was determined after 6 days. Cell viability relative to its own respective control transfected with scramble siRNA was calculated, n = 2–3 with SEM (*p < 0.05). i SUM159PT cells were treated with multiple small molecules inhibitors against several signaling pathways for 24 h and PDGFRβ levels were determined by western blot. j Kaplan-Meier survival analysis of the relationship between PDGFRβ mRNA expression and clinical outcomes in breast cancer patients treated with or without chemotherapy using the KMplotter dataset (http://kmplot.com/). PDGFRβ expression stratified on relapse free survival. k SUM159PT cells were treated with different concentration of PDGFRβ inhibitors for 24 h and the levels of growth and survival-related proteins were determined using western blot